$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2012 Q3 Form 10-Q Financial Statement

#000106282212000037 Filed on August 02, 2012

Income Statement

Concept	2012 Q3	2012 Q2	2011 Q2
Revenue	$372.0K	$199.0K	$555.0K
YoY Change	4.79%	-64.14%	-54.99%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.400M	$5.100M	$5.400M
YoY Change	7.32%	-5.56%	5.88%
% of Gross Profit
Research & Development	$19.19M	$19.36M	$20.15M
YoY Change	-2.36%	-3.92%	-0.46%
% of Gross Profit
Depreciation & Amortization	$1.100M	$1.100M	$1.300M
YoY Change	-8.33%	-15.38%	0.0%
% of Gross Profit
Operating Expenses	$29.43M	$25.68M	$26.48M
YoY Change	13.0%	-3.03%	4.64%
Operating Profit	-$29.06M	-$25.48M	-$25.93M
YoY Change	13.11%	-1.72%	7.69%
Interest Expense	$527.0K	$530.0K	$810.0K
YoY Change	-5.89%	-34.57%	11.11%
% of Operating Profit
Other Income/Expense, Net	$4.000K	$21.00K	$30.00K
YoY Change	-95.45%	-30.0%	-104.67%
Pretax Income	-$29.50M	-$25.90M	-$26.60M
YoY Change	13.01%	-2.63%	5.56%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$29.54M	-$25.93M	-$26.64M
YoY Change	13.16%	-2.65%	5.74%
Net Earnings / Revenue	-7940.59%	-13030.65%	-4799.64%
Basic Earnings Per Share
Diluted Earnings Per Share	-$421.4K	-$377.0K	-$551.9K
COMMON SHARES
Basic Shares Outstanding	494.3M shares	480.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q3	2012 Q2	2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$206.4M	$231.1M	$164.4M
YoY Change	43.63%	40.57%	-39.51%
Cash & Equivalents	$20.76M	$33.78M	$20.33M
Short-Term Investments	$185.7M	$197.3M	$144.1M
Other Short-Term Assets	$9.004M	$6.582M	$3.874M
YoY Change	107.61%	69.9%	-54.95%
Inventory
Prepaid Expenses
Receivables	$233.0K	$182.0K	$505.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$216.1M	$238.3M	$169.2M
YoY Change	45.04%	40.83%	-40.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$43.52M	$44.53M	$48.37M
YoY Change	-8.09%	-7.95%	-14.54%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%
Intangibles	$53.56M	$53.56M	$53.56M
YoY Change	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$135.0K	$157.0K	$253.0K
YoY Change	-51.96%	-37.94%	-36.75%
Total Long-Term Assets	$141.8M	$142.8M	$146.7M
YoY Change	-2.73%	-2.69%	77.42%
TOTAL ASSETS
Total Short-Term Assets	$216.1M	$238.3M	$169.2M
Total Long-Term Assets	$141.8M	$142.8M	$146.7M
Total Assets	$357.8M	$381.1M	$315.9M
YoY Change	21.42%	20.62%	-13.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.306M	$4.579M	$3.671M
YoY Change	-22.08%	24.73%	4.89%
Accrued Expenses	$12.78M	$15.05M	$8.037M
YoY Change	65.94%	87.2%	27.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.542M	$1.510M	$1.380M
YoY Change	9.13%	9.42%	-91.93%
Total Short-Term Liabilities	$19.05M	$21.56M	$13.23M
YoY Change	28.67%	62.97%	-51.73%
LONG-TERM LIABILITIES
Long-Term Debt	$22.28M	$22.68M	$24.19M
YoY Change	-6.47%	-6.24%	-13.3%
Other Long-Term Liabilities	$31.09M	$59.28M	$51.36M
YoY Change	-42.04%	15.42%	247.01%
Total Long-Term Liabilities	$53.37M	$81.95M	$75.55M
YoY Change	-31.1%	8.48%	76.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.05M	$21.56M	$13.23M
Total Long-Term Liabilities	$53.37M	$81.95M	$75.55M
Total Liabilities	$105.1M	$136.2M	$121.7M
YoY Change	-16.09%	11.86%	73.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$875.0M	-$845.4M	-$729.7M
YoY Change	15.77%	15.86%
Common Stock	$495.0K	$481.0K	$338.0K
YoY Change	46.45%	42.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$630.0K	$630.0K	$345.0K
YoY Change	82.61%	82.61%
Treasury Stock Shares	380.0K shares	380.0K shares	218.0K shares
Shareholders Equity	$252.8M	$244.9M	$194.2M
YoY Change
Total Liabilities & Shareholders Equity	$357.8M	$381.1M	$315.9M
YoY Change	21.42%	20.62%	-13.5%

Cashflow Statement

Concept	2012 Q3	2012 Q2	2011 Q2
OPERATING ACTIVITIES
Net Income	-$29.54M	-$25.93M	-$26.64M
YoY Change	13.16%	-2.65%	5.74%
Depreciation, Depletion And Amortization	$1.100M	$1.100M	$1.300M
YoY Change	-8.33%	-15.38%	0.0%
Cash From Operating Activities	-$25.00M	-$22.00M	-$23.70M
YoY Change	23.76%	-7.17%	4.87%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$100.0K	-$300.0K
YoY Change	-50.0%	-66.67%	200.0%
Acquisitions
YoY Change
Other Investing Activities	$11.70M	$26.90M	$26.80M
YoY Change	-62.14%	0.37%	-10.67%
Cash From Investing Activities	$11.60M	$26.90M	$26.50M
YoY Change	-62.21%	1.51%	-11.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	500.0K	-200.0K	-2.600M
YoY Change	-225.0%	-92.31%	-86.87%
NET CHANGE
Cash From Operating Activities	-25.00M	-22.00M	-23.70M
Cash From Investing Activities	11.60M	26.90M	26.50M
Cash From Financing Activities	500.0K	-200.0K	-2.600M
Net Change In Cash	-12.90M	4.700M	200.0K
YoY Change	-227.72%	2250.0%	-101.61%
FREE CASH FLOW
Cash From Operating Activities	-$25.00M	-$22.00M	-$23.70M
Capital Expenditures	-$100.0K	-$100.0K	-$300.0K
Free Cash Flow	-$24.90M	-$21.90M	-$23.40M
YoY Change	24.5%	-6.41%	4.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6042000	USD
CY2012Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4579000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	350000	USD
CY2012Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	182000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13786000	USD
CY2012Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15045000	USD
CY2012Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	82576000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	4243000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9285000	USD
CY2012Q2	us-gaap	Assets Current AssetsCurrent	238277000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80535000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20000	USD
CY2012Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1090485000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1087033000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2922000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3313000	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2012Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2012Q2	us-gaap	Assets Assets	381060000	USD
CY2011Q4	us-gaap	Assets Assets	430512000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	285790000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186309000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33779000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47208000	USD
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20328000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-152530000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-26880000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	481000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	480000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56201000	USD
CY2011Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26607000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-851000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25894000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55840000	USD
CY2011Q2	us-gaap	Contracts Revenue ContractsRevenue	461000	USD
CY2012Q2	us-gaap	Contracts Revenue ContractsRevenue	199000	USD
	us-gaap	Contracts Revenue ContractsRevenue	977000	USD
	us-gaap	Contracts Revenue ContractsRevenue	351000	USD
CY2012Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	119000	USD
CY2012Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	421000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14212000	USD
CY2012Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13910000	USD
CY2012Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2571000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2219000	USD
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2862000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	4243000	USD
CY2010Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	48267000	USD
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	59276000	USD
CY2011Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	51129000	USD
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	55033000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4162000	USD
CY2011Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4532000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8727000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2012Q2	us-gaap	Goodwill Goodwill	44543000	USD
CY2012Q2	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	2600000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	785000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2360000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	317000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-239000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-168000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	76000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	366000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	48000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2834000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-991000	USD
CY2012Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
	us-gaap	Interest Expense InterestExpense	1067000	USD
	us-gaap	Interest Expense InterestExpense	1417000	USD
CY2011Q2	us-gaap	Interest Expense InterestExpense	810000	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	530000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1029000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1385000	USD
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	58000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	155000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	114000	USD
CY2011Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	68000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	132944000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	276000	USD
CY2012Q2	us-gaap	Liabilities Liabilities	136164000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	430512000	USD
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	381060000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21390000	USD
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21555000	USD
CY2011Q2	us-gaap	Licenses Revenue LicensesRevenue	94000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	188000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-136000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-102720000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21184000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45229000	USD
CY2012Q2	us-gaap	Licenses Revenue LicensesRevenue	0	USD
	us-gaap	Licenses Revenue LicensesRevenue	174000	USD
	us-gaap	Licenses Revenue LicensesRevenue	148000	USD
CY2011Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1443000	USD
CY2012Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1510000	USD
CY2011Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23451000	USD
CY2012Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	22678000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2835000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48959000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-55799000	USD
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-26638000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56267000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-25931000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	25679000	USD
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	26481000	USD
	us-gaap	Operating Expenses OperatingExpenses	55362000	USD
	us-gaap	Operating Expenses OperatingExpenses	56213000	USD
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-25926000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-55062000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54863000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-25480000	USD
CY2012Q2	us-gaap	Other Assets Current OtherAssetsCurrent	6582000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3748000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	205000	USD
CY2012Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	157000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-41000	USD
CY2011Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	31000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	37000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	66000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55146000	USD
CY2012Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	59276000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17000	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	57000	USD
CY2011Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	108000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	285000	USD
CY2012Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	64126000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	151776000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	329000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	815000	USD
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	83609000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	49384000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2516000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	USD
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44526000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46417000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	706000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2915000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44066000	USD
CY2011Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20145000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42392000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19355000	USD
CY2011Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2012Q2	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2012Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-845420000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-789621000	USD
	us-gaap	Revenues Revenues	499000	USD
CY2011Q2	us-gaap	Revenues Revenues	555000	USD
CY2012Q2	us-gaap	Revenues Revenues	199000	USD
	us-gaap	Revenues Revenues	1151000	USD
CY2012Q2	us-gaap	Secured Debt SecuredDebt	24200000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3313000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2922000	USD
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost	1500000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost	2900000	USD
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost	1600000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost	3300000	USD
CY2012Q2	us-gaap	Short Term Investments ShortTermInvestments	197734000	USD
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	95383000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	276000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	551000	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	244896000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	297568000	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	247024000	USD
CY2012Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	244896000	USD
CY2011Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	194188000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	297568000	USD
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	218000	shares
CY2012Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	380000	shares
CY2012Q2	us-gaap	Treasury Stock Value TreasuryStockValue	630000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	345000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	285000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	108000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	66000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-41000	USD
CY2012Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2162000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2862000	USD
CY2011Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1804000	USD
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	7650622	shares
	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	480479000	shares
	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	337598000	shares
CY2011Q2	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	337668000	shares
CY2012Q2	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	480634000	shares
CY2012Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	680000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1265000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1361000	USD
CY2011Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	632000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1952000	USD
CY2011Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	818000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1657000	USD
CY2012Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	915000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	13237519	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Period End Date DocumentPeriodEndDate	2012-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2012Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	494336148	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name	View Source	Status
0001062822-12-000037-index-headers.html	Edgar Link	pending
0001062822-12-000037-index.html	Edgar Link	pending
0001062822-12-000037.txt	Edgar Link	pending
0001062822-12-000037-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
lxrx-20120630.xml	Edgar Link	completed
lxrx-20120630.xsd	Edgar Link	pending
lxrx-20120630_cal.xml	Edgar Link	unprocessable
lxrx-20120630_def.xml	Edgar Link	unprocessable
lxrx-20120630_lab.xml	Edgar Link	unprocessable
lxrx-20120630_pre.xml	Edgar Link	unprocessable
lxrx630201210-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2012 Q3 Form 10-Q Financial Statement

#000106282212000037 Filed on August 02, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2012 Q3 Form 10-Q Financial Statement

#000106282212000037 Filed on August 02, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx